1. This preparation has the effect of reducing fibrinogen, and there may be bleeding or delayed hemostasis after taking it. Therefore, patients should be examined for fibrinogen and platelet aggregation before and during treatment, and pay close attention to clinical symptoms. If the fibrinogen is lower than 100mg/dl for the first time after the first medication, the medication should be stopped and blood transfusion or other measures should be taken when bleeding or suspicious bleeding occurs during the medication. 2. If the patient has arterial or deep vein injury, the drug may cause hematoma. Therefore, after using this preparation, the clinical examination or treatment of stellate ganglion occlusion, artery or deep vein puncture should be avoided. When there is a phenomenon of delayed hemostasis at the superficial venipuncture site, compression hemostasis should be adopted. 3. In order to make the patient understand the possibility of bleeding after using this preparation, it is necessary to inform the patient of the following matters: 1) Discuss with the doctor before using this preparation during surgery or tooth extraction. 2) When going to other hospitals or departments for treatment, the doctor should be informed of the use of this preparation. 3) Avoid any work that may cause trauma during medication. 4. Use with caution in the following patients: 1) those with a history of drug allergy; 2) Those with a history of digestive tract ulcer; 3) Patients with sequelae of cerebrovascular disease.